Skip to the essay

Patient notes · November 2026

GLP-1 Journey

What the weeks feel like, from appetite to maintenance. No invented patient stories.

Note

Maintenance, and what happens if the medicine stops

Maintenance is the part of treatment the ads compress into a single “before and after.” Labels for Wegovy and Zepbound say the drugs are indicated to reduce excess body weight and to maintain weight reduction long term, together with diet and physical activity. The long term is the point. Obesity behaves like a chronic condition in the withdrawal trials: when the drug and, in one study, the lifestyle support stop, much of the lost weight returns. This note cites those trials and stays out of do-it-yourself tapering schedules, because the labels do not provide a casual off-ramp you can invent at home.

Staying on a tolerated dose

Wegovy’s adult weight-reduction maintenance is 1.7 mg or 2.4 mg once weekly, with 2.4 mg the dose the label calls recommended. A move to 7.2 mg is optional and conditional: the person has tolerated 2.4 mg for at least four weeks, and additional weight reduction is clinically indicated. Zepbound’s maintenance choices are 5, 10, or 15 mg weekly. For obstructive sleep apnea the label’s recommended maintenance is 10 or 15 mg, not the 5 mg option used for weight reduction alone. Saxenda’s recommended adult dose is 3 mg daily, and lower doses are described as titration. If 3 mg is not tolerated, the Saxenda label says to discontinue, which is harsher than Zepbound’s “consider a lower maintenance dose.” Product choice changes the maintenance rules. Confirm which label you are under. The plateau note is about stalls while you are still in treatment. This one is about the months after the stall, and about stopping.

NIDDK is explicit that weight-management medicines do not replace physical activity or healthy eating and that they work best with a lifestyle program. The eating pattern NIDDK summarizes, vegetables, fruit, whole grains, protein foods, dairy, and limits on added sugar, saturated fat, and sodium, does not expire when the dose stabilizes. Protein and strength work matter more, not less, once the rate of loss slows, because the goal shifts toward keeping function. What to eat is the food note to return to. It does not become obsolete at month six.

Follow-up still has medical content. Labels want clinicians to watch gastrointestinal tolerance, and they warn about gallbladder disease, pancreatitis symptoms, and dehydration-related kidney injury throughout treatment, not only in week one. People with diabetes still need glucose reviewed when insulin or a sulfonylurea is on the list. Heart-rate increases were observed in the Wegovy program. None of that becomes irrelevant because the scale is quieter.

What happened when semaglutide was withdrawn in trials

STEP 4 randomized adults who had already completed 20 weeks of semaglutide, mean loss about 10.6 percent, either to continue semaglutide 2.4 mg or to switch to placebo for another 48 weeks. Lifestyle intervention continued in both groups. From the point of randomization to week 68, mean weight change was −7.9 percent with continued semaglutide and +6.9 percent with placebo. Waist circumference and systolic blood pressure also favored staying on the drug. Gastrointestinal events were still more common in the people who continued it (49.1 percent versus 26.1 percent). Continued treatment was not free. Withdrawal was not weight-neutral.

The STEP 1 extension asked a harsher version of the question. Participants had completed 68 weeks of semaglutide or placebo plus lifestyle intervention. Then treatment, including the lifestyle intervention, stopped, and a subset was observed for another year. In that extension sample, mean loss from week 0 to week 68 was 17.3 percent with semaglutide. After withdrawal, those participants regained 11.6 percentage points by week 120, for a net loss of 5.6 percent from the original baseline. The authors’ summary is that participants regained about two-thirds of the prior loss, and that cardiometabolic improvements largely moved back toward baseline. The paper is explicit that this was an exploratory extension in a subset, not the whole original trial, and that lifestyle support was not continued during the off-treatment year. It is still the clearest public evidence that stopping both the drug and the support is followed by regain.

SURMOUNT-1 showed large mean losses at 72 weeks on tirzepatide while treatment continued. It is not, by itself, a withdrawal study. Do not borrow STEP 1’s regain figures and paste them onto tirzepatide as if the trials were the same design. Do not borrow them as a personal prediction either. They are averages with wide individual spread. They are enough to retire the idea that a few months of injections reset body weight permanently for the typical participant.

If you and your clinician decide to stop

Reasons people stop are real: pregnancy planning, intolerable side effects, cost, a surgery plan, or a conclusion that the benefit was not worth the burden. Wegovy’s label says to discontinue at least two months before a planned pregnancy for the weight-reduction and cardiovascular uses, because of the long half-life, and to stop when pregnancy is recognized. That is one of the few timing instructions the label actually gives about stopping. It is not a general taper schedule for someone who is done losing weight.

There is no home protocol in the label that says “take it every other week for a month, then stop.” Inventing one can mean a period of unpredictable drug levels plus the gastrointestinal risk of irregular dosing. If cost is the reason, the more direct conversation is about manufacturer self-pay offers, insurance, and whether a labeled product you can afford exists. Those are coverage questions, handled on the cash-price sheet, not by stretching a pen past its instructions for use.

If side effects are the reason, stopping can be the right outcome and still deserves a plan for nutrition. Appetite often returns. The STEP 1 extension is what return of weight looked like in a studied group. Preparing for that, with the same food pattern and activity NIDDK describes, is more honest than a promise that habits alone will reproduce the on-treatment mean. Some weight was still below baseline a year later in that extension. Most of the lost weight was not.

What to keep measuring

Whether you stay on the drug or come off it, a few measures tell you more than a single morning weight: the trend over a month, waist if you use it, blood pressure if it was a reason for treatment, glucose measures if you have diabetes or prediabetes, and whether you can do the strength work you could do last season. Hair shedding, constipation, and reflux can continue or fade on their own timetables. New severe abdominal pain is never a maintenance footnote. It is the pancreatitis and gallbladder warning, and it belongs with a clinician the day it is severe.

A practical maintenance visit, if you stay on treatment, can be short and still be real. Bring the dose you are actually taking, not the dose you were promised at the first appointment. Bring any weeks you skipped for travel, cost, or side effects. Bring blood pressure or glucose readings if those were reasons you started. Ask whether the maintenance dose is still the labeled one for your indication, because sleep apnea and weight reduction do not always share the same Zepbound maintenance options. Ask what should trigger an earlier visit than the routine one. That list is usually the warning symptoms, a pregnancy, a planned surgery, or a stretch of vomiting. None of it requires a new product. It requires the same prescriber relationship the escalation phase already depended on.

Side effects remains the symptom list. The first twelve weeks remains the picture of how slow the start was, which is worth remembering if you ever restart and someone offers you your old maintenance dose on day one. Restarting at the top is not what the escalation tables say. This notebook will not write you a taper. It will point at the trials that explain why the conversation matters, and at the prescriber who has to have it with you.

Sources we used

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC7988425/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/
  3. https://pubmed.ncbi.nlm.nih.gov/33567185/
  4. https://pubmed.ncbi.nlm.nih.gov/35658024/
  5. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  6. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
  7. https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/eating-physical-activity
  8. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity